Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Metabolic Disorders Gastrointestinal Infectious Diseases

Once-weekly Byetta shows superiorty over oral antidiabetics in Phase III

This article was originally published in Scrip

Executive Summary

Lilly/ Amylin's once-weekly version of the twice-daily injectable diabetes drug Byetta (exenatide), a GLP-1 analogue, has been shown in a Phase III trial to provide improved glucose control and weight loss than two oral antidiabetics, Merck & Co's DPP-4 inhibitor Januvia (sitagliptin) and Takeda's thiazolidinedione Actos (pioglitazone), in patients with type 2 diabetes who were inadequately controlled on metformin.

Table

View full table

Topics

Related Companies

Tags:
Metabolic Disorders Gastrointestinal Infectious Diseases
Latest Headlines

Amgen Planning Pivotal Obesity Program For MariTide

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

See All
UsernamePublicRestriction

Register

SC001302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By